Aprea Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Aprea Therapeutics, Inc. filed a Form 8-K dated October 7, 2019. The company completed its initial public offering of common stock and, in connection with the offering, filed an amended and restated certificate of incorporation and adopted amended and restated bylaws.
Financial and Liquidity Information
This filing does not provide financial statements, revenue, profit, cash flow, margin, debt, liquidity, or other operating metrics. The filing text does not provide the size or proceeds of the initial public offering.
Material Changes Versus the Prior Comparable Period
- The company’s certificate of incorporation was amended and restated effective upon completion of the initial public offering.
- Amended and restated bylaws were adopted effective October 7, 2019.
- The documents had been previously approved by the board of directors and stockholders and became effective in connection with the offering.
Guidance, Outlook, Risks, and Unusual Items
No financial guidance or operating outlook is provided. The filing refers investors to the company’s October 4, 2019 prospectus for descriptions of the amended governance documents, risk factors, management, and capital stock. The amended and restated certificate and bylaws are filed as Exhibits 3.1 and 3.2.
Key Facts for Investors to Verify
- Review the full amended and restated certificate of incorporation and bylaws for changes affecting corporate governance, shareholder rights, and capital structure.
- Review the October 4, 2019 prospectus for the initial public offering terms, offering proceeds, dilution, risk factors, and use of proceeds.
- Confirm the company’s common stock trades under the symbol APRE on the Nasdaq Global Select Market.
- Note that Aprea identified itself as an emerging growth company and elected not to use the extended transition period for complying with new or revised accounting standards.